GET DAILY SIGNALSAfya Limited (AFYA): Insights into Brazil's Leading Private Medical Education Provider
Key Takeaways
- AFYA is the Nasdaq-listed ticker for Afya Limited, a leading private medical education group in Brazil.
- The company operates three business segments: Undergraduate, Continuing Education, and Medical Practice Solutions.
- Afya generates the large majority of its revenue from medical school tuition, with a growing digital health and physician-services business.
- The company is majority-owned by German media and education conglomerate Bertelsmann and listed on the Nasdaq since July 2019.
- Afya's "company overview" is defined by its end-to-end, physician-centric ecosystem spanning education through clinical practice support.
Background and Market Position
Afya Limited has developed one of the largest private networks of medical schools in Brazil, Latin America's largest economy. Its shares trade on the Nasdaq Global Select Market under the symbol AFYA. The company operates in a structurally attractive niche where the supply of new physicians is tightly regulated, and demand for medical education consistently exceeds available seats. This setup creates high barriers to entry and pricing power for established players.
Origins and Business Structure
Afya traces its roots to 1999, when the Esteves family started assembling a group of medical and health education institutions in Brazil. The holding company was incorporated in the Cayman Islands in March 2019 and completed its IPO on the Nasdaq in July 2019. Headquarters are in Nova Lima, in the Belo Horizonte area of Minas Gerais. German conglomerate Bertelsmann SE & Co. KGaA serves as the ultimate parent company.
Afya positions itself as an end-to-end physician-centric ecosystem that supports students from undergraduate training through their professional careers. Operations fall into three reportable segments. The Undergraduate segment forms the core, delivering medical and health sciences degrees along with some non-health programs, and it accounts for roughly 88% of revenue in recent fiscal years. The Continuing Education segment offers residency preparation, specialization courses, and professional development through brands like Medcel and Pebmed. The Medical Practice Solutions segment focuses on digital health tools, including the Whitebook clinical decision app and iClinic practice management platform.
Revenue comes mainly from tuition and fees, supported by government-backed financing under Brazil's FIES program, the company's own credit options, and subscription-based digital products. Growth has also come through acquisitions, such as Unidom in 2024 and DelRey in 2023, which expanded medical school capacity and geographic reach. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
In competitive terms, Afya ranks among the leading private providers by authorized medical school seats. Rivals include other Brazilian education groups such as Yduqs and Vitru. Medical school authorizations from Brazil's Ministry of Education limit new entrants, supporting the company's market position.
Why Investors Track AFYA
Investors follow AFYA for its exposure to Brazil's healthcare and education sectors through a hard-to-replicate set of assets. Medical school seats represent a scarce, regulated resource, and once authorized, they mature to full enrollment over several years, offering revenue visibility. This supports a financial profile with relatively stable, recurring tuition income and solid cash generation.
Long-term demographic and policy trends add support. Brazil faces an ongoing physician shortage relative to its population, and demand for medical education has outpaced supply. The digital health offerings extend the relationship with physicians beyond graduation. A strategy of acquiring regional institutions provides a route to grow capacity and enter new areas.
Risks and Key Considerations
Several risks warrant attention. The company faces heavy exposure to Brazil's regulatory environment, as the Ministry of Education oversees seat authorizations and tuition practices. Changes to rules, financing programs like FIES, or pricing policies could affect results.
Macroeconomic factors matter as well. Tuition revenue depends on students' ability to pay, which can shift with economic cycles, inflation, and interest rates. Afya carries debt in Brazilian reais, and results are translated into U.S. dollars for Nasdaq reporting, so currency moves can influence figures for U.S. investors.
Operationally, competition for students exists in some regions, and the acquisition-driven model brings integration risks. Regulatory quality reviews of programs can also create challenges. These elements deserve careful evaluation.
Exploring Opportunities with Tickeron’s AI Screener
In my own research process, I regularly use Tickeron’s AI Screener to scan for stocks that align with specific criteria in sectors like education and healthcare. The platform allows filtering by technical indicators, fundamentals, trends, and AI signals, helping surface ideas that match individual strategies. It has become a useful step when evaluating names such as AFYA alongside peers.
Final Thoughts
Afya Limited offers a focused way to access Brazil's regulated medical education market. Its combination of a leading school network, digital products that extend across a physician's career, recurring tuition revenue, and acquisition strategy shapes both its business model and long-term outlook. For those seeking emerging-market exposure in healthcare and education, the company's position built on scarcity and regulation stands out.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AFYA in downward trend: 10-day moving average moved below 50-day moving average on October 28, 2026
The 10-day moving average for AFYA crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AFYA as a result. In 60 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for AFYA turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 31 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
AFYA moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AFYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for AFYA entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AFYA's RSI Oscillator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 54 cases where AFYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where AFYA advanced for three days, in 214 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
AFYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. AFYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.190) is normal, around the industry mean (1.158). P/E Ratio (1.203) is within average values for comparable stocks, (8.484). AFYA's Projected Growth (PEG Ratio) (5.160) is very high in comparison to the industry average of (1.327). Dividend Yield (0.500) settles around the average of (4.151) among similar stocks. P/S Ratio (1.661) is also within normal values, averaging (27.566).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AFYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical education group in Brazil, which delivers an end-to-end physician-centric ecosystem that serves and empowers students to be lifelong medical learners through their medical residency preparation, post-graduate programs and continuing medical education activities
Industry OtherConsumerSpecialties
Advertisement